Literature DB >> 11305699

Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation.

G W Currier1, G M Simpson.   

Abstract

BACKGROUND: Although agitation associated with psychosis is a common presentation in the psychiatric emergency service, there is no consensus concerning the best treatment. Standard treatment often consists of intramuscular (i.m.) injection of high-potency neuroleptics, sometimes combined with benzodiazepines. The objective of this study was to determine the relative efficacy, safety, and tolerability of oral risperidone versus intramuscular haloperidol, both in combination with lorazepam, for the emergency treatment of psychotic agitation in patients who are able to accept oral medications.
METHOD: A convenience sample of psychotic patients admitted to a large psychiatric emergency service who required emergency medication for the control of agitation and/or violence was offered risperidone (2 mg liquid concentrate) and oral lorazepam (2 mg) as an alternative to standard care at the institution, haloperidol (5 mg i.m.) and lorazepam (2 mg i.m.). Subjects who refused the oral medications were given the intramuscular treatment as a component of routine care.
RESULTS: Thirty patients were enrolled in each treatment group. Although men were significantly more likely to choose oral medication (chi2 = 5.165, p < .023), other demographic characteristics did not differ significantly between the 2 treatment groups. Both groups showed similar improvement in agitation as measured by 5 agitation subscales of the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions (CGI) scale, and time to sedation. No patients receiving risperidone demonstrated any side effects or adverse events, while 1 patient receiving intramuscular treatment with haloperidol developed acute dystonia. One subject receiving risperidone required subsequent treatment with haloperidol for ongoing agitation.
CONCLUSION: Oral treatment with risperidone and lorazepam appears to be a tolerable and comparable alternative to intramuscular haloperidol and lorazepam for short-term treatment of agitated psychosis in patients who accept oral medications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11305699     DOI: 10.4088/jcp.v62n0303

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  19 in total

1.  Organisational interventions for preventing and minimising aggression directed towards healthcare workers by patients and patient advocates.

Authors:  Evelien Spelten; Brodie Thomas; Peter F O'Meara; Brian J Maguire; Deirdre FitzGerald; Stephen J Begg
Journal:  Cochrane Database Syst Rev       Date:  2020-04-29

2.  Atypical antipsychotics: sleep, sedation, and efficacy.

Authors:  Del D Miller
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 3.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder.

Authors:  Gabrielle A Carlson; Michael Potegal; David Margulies; Joann Basile; Zinoviy Gutkovich
Journal:  Bipolar Disord       Date:  2010-03       Impact factor: 6.744

Review 5.  Pharmacological treatment of psychotic agitation.

Authors:  Glenn W Currier; Adam Trenton
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 6.  Pharmacological management of acute agitation.

Authors:  John Battaglia
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Authors:  A Cario Altamura; Francesca Sassella; Annalisa Santini; Clauno Montresor; Sara Fumagalli; Emanuela Mundo
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Pharmacological management of agitation in emergency settings.

Authors:  A Yildiz; G S Sachs; A Turgay
Journal:  Emerg Med J       Date:  2003-07       Impact factor: 2.740

9.  New treatments for agitation.

Authors:  Leslie Citrome
Journal:  Psychiatr Q       Date:  2004

Review 10.  [Psychopharmacological treatment in the pre-clinical emergency medicine].

Authors:  F-G Pajonk; B Fleiter
Journal:  Anaesthesist       Date:  2003-07-10       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.